Efficacy Analysis of Calcium Dobesilate Combined with Irbesartan in Treatment of the Early Diabetic Nephropathy

ZHAO Cai-ling

doi:10.14033/j.cnki.cfmr.2015.29.010

Abstract：Objective:To analyze the clinical curative effect and value of the calcium dobesilate combined with irbesartan in treatment of early diabetic nephropathy.Method: According to the patient number,92 patients with early diabetic nephropathy in our hospital from September 2014 to May 2015 were divided into the control group and the observation group,46 cases in each group.The control group was received Irbesartan treatment,the observation group was received calcium irbesartan treatment.Treatment with a course of two months.Before and after treatment, the clinical parameters were measured, and the results were analyzed of the two groups.Result: Before and after treatment,the fasting plasma glucose(FPG),serum creatinine (Scr),mean arterial pressure(MAP) and glycosylated hemoglobin(HbA1c) levels of the two groups,which had no significant change(P>0.05), and there was no significant difference between the two groups(P>0.05);after treatment,24 h urinary albumin excretion rate (UAER) levels of the two groups were significantly lower than before treatment(P<0.05),and the observation group decreased more significantly than the control group(P<0.05); the total effective rate of the control group and the observation group were 39.13% and 80.43%, the observation group was better than the control group, there was statistical differences significance(P<0.05).Conclusion:Give calcium dobesilate and irbesartan in treatment of the patiens with early diabetic nephropathy,which helps to reduce the urinary albumin excretion, and effectively improve the therapeutic effect,it is worthy of promotion.